Companies in #COVID-19
Found 3 companies operating in this sector.
Clinical-stage biotechnology company developing monoclonal antibodies for infectious diseases, with a focus on long-acting immunologic prophylaxis. Lead product pemivibart targets SARS-CoV-2 prevention.
Novavax is a vaccine company built on a recombinant protein-based nanoparticle platform and its saponin-based Matrix-M adjuvant, used in Nuvaxovid (NVX-CoV2373), its protein-based COVID-19 vaccine. The company develops adjuvanted vaccines for infectious diseases and partners with public-health bodies and manufacturers on supply and technology transfer.
Traws Pharma is a clinical-stage biopharmaceutical company developing oral small-molecule antiviral therapies for critical global viral threats, with clinical programs targeting H5N1 bird flu, seasonal influenza, and COVID-19 / Long COVID. Lead candidate tivoxavir marboxil is being advanced for H5N1 bird flu with a human challenge trial planned in the United Kingdom, and ratutrelvir (TRX0) is being developed as a ritonavir-independent COVID-19 therapy. The company filed a registration statement for an unspecified securities offering in July 2026 and maintains a $50 million at-the-market facility from March 2025 to support clinical development.